Ystem

Ystem is a South Korean biotechnology company specializing in the development of regenerative medicines using adipose-derived mesenchymal stem cells (ADSCs). The company focuses on treating degenerative diseases and aesthetic conditions through its proprietary platform for stem cell isolation, culture, and differentiation. Its lead candidate, YS-101, is a cell therapy currently in clinical development for knee osteoarthritis, designed to promote cartilage repair and reduce joint inflammation. Additionally, Ystem is advancing programs for alopecia and skin rejuvenation, leveraging the immunomodulatory and regenerative properties of ADSCs. By utilizing adipose tissue as a source, the company aims to provide a more accessible and scalable approach to cell therapy compared to traditional bone marrow-derived methods. The company's technology ensures high purity and potency of the final cell product, addressing key challenges in the commercialization of stem cell therapies.